BUFFALO, N.Y. – Researchers have shown for the first time that intermittent fasting increases the efficacy of anti-androgen therapy in prostate cancer, according to a paper reporting preclinical ...
Triplet therapy with ADT, darolutamide, and biweekly docetaxel for high-risk metastatic castration-sensitive prostate cancer (TRIC): An open-label, single-arm phase II clinical trial. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results